Addendum
Isatuximab (multiple myeloma after >= 2 prior therapies, combination with pomalidomide and dexamethasone) - Addendum to Commission A21-61
Report documents
-
Addendum
Isatuximab (multiple myeloma after >= 2 prior therapies, combination with pomalidomide and dexamethasone) - Addendum to Commission A21-61
Dossier assessment
Indication:
Adult patients with relapsed and refractory multiple myeloma who have received ≥ 2 prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy
Result of dossier assessment:
Unchanged after addendum: Added benefit not proven
Additional information
Federal Joint Committee (G-BA)
04-11-2021 A G-BA decision was published.
Project details
- Project no.
- A21-124
- Commission
- Commission awarded on 30.09.2021 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Isatuximab (multiple myeloma after >= 2 prior therapies, combination with pomalidomide und dexamethasone) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed